WO2010097643A1 - Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite - Google Patents

Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite Download PDF

Info

Publication number
WO2010097643A1
WO2010097643A1 PCT/HR2009/000005 HR2009000005W WO2010097643A1 WO 2010097643 A1 WO2010097643 A1 WO 2010097643A1 HR 2009000005 W HR2009000005 W HR 2009000005W WO 2010097643 A1 WO2010097643 A1 WO 2010097643A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
polyoxyethylene
acid
substances
sodium
Prior art date
Application number
PCT/HR2009/000005
Other languages
English (en)
French (fr)
Inventor
Antonio Lelas
Ivica Cepanec
Original Assignee
Novatech Istrazivanje D.O.O.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novatech Istrazivanje D.O.O. filed Critical Novatech Istrazivanje D.O.O.
Priority to PCT/HR2009/000005 priority Critical patent/WO2010097643A1/en
Publication of WO2010097643A1 publication Critical patent/WO2010097643A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Definitions

  • the present invention relates to a formulation comprising micronized zeolite, green tea extract, genistein, and one or more optional ingredients which is used as an effective therapeutic agent for reduction of body weight and cellulite.
  • the present invention solves technical problem of efficient reduction of body weight and cellulite, based on formulation consisting of variable portions of:
  • micronized zeolite (MZ) of general formula:
  • Me Na, K, Mg, Ca, Fe, Zn, Mn, Cr; whereas ratio of silicon to aluminium, y:x is between 6:1 to 1 :1 ; number of crystalline water m is from 0 to 20, which is characterized by particles size ⁇ 5 ⁇ m; in concentrations from 1-50%, most preferably from 3-30%;
  • Green tea extract containing at least 30% of epigallocatechin gallate (EGCG; 1), and 5% of caffeine (2); in concentrations from 0.1-90%, most preferably from 20-90%; 1
  • EGCG epigallocatechin gallate
  • excipients which yield in desired pharmaceutical or cosmetic form: tablets, capsules, ointments, creams, gels, lotions, shampoos, powders, liquid powders, syrups, suspensions, and therapeutic patches; in concentrations from 1-98.85%, most preferably from 10-75%.
  • Obesity condition is one of the major risk factors for a numerous diseases of modern people such as hypertension, increased blood triglycerides and cholesterol, atherosclerosis, diabetes, etc. Increased body weight also causes several cosmetic disadvantages in both female and male subjects.
  • One of the most known conditions within female population is enhanced occurrence of cellulite.
  • the obesity and accompanied condition of cellulite in female subjects can be treated with numerous commercial herbal and over-the-counter preparations. Some of them are based on natural substances which physically adsorbs fatty substances in the gastrointestinal (GI) tract. In this manner they impair absorption of fats in GI tract, and help to eliminate them by feces. Other active substances act at some levels of metabolism by speeding-up the catabolism of triglycerides.
  • GI gastrointestinal
  • Green tea extract due to its content of epigallocatechin gallate (1), and caffeine (2) has been used for treatment of obesity, cellulite, and associated metabolic syndrome both as single ingredient or in combinations with kidney bean extracts [G. S. Birketvedt, CA2627314 (2007)], pregnane glycosides [R. Kamala, R. Ramaswamy, CA2563952 (2005)], pine needle extract [J. Y. Kim, KR20040089258 (2004)], etc.
  • EGCG (1) is effective in treatment of obesity due to its strong lipolytic and antioxidative effects:
  • (iii) inhibits the lipid accumulation in 3T3-L1 cells, generally reduces adipose tissue mass, and promote thermogenesis and fat oxidation at obesity condition
  • Caffeine (2) promotes lipolysis upon metabolic conversion to paraxanthine (under the action of cytochrome P450 oxidase). In this manner it can raise concentration of triglycerides lipolytic products: glycerol and higher fatty acids.
  • Green tea extract helps reduction of body weight and cellulite by combination of the following pathways:
  • Genistein (3) has been described as an effective agent for treatment of obesity [I. Schoenmakers, C. Z. Dang, M. G. W. C. L ⁇ wik, B. L. A. Van Helvoort, R. Hageman, WO 03/068218 Al (2003); C. Prasad, E. J. Figueroa, P. Vijayagopal, US2006182825 Al (2006)].
  • genistein Due to the fact that cellulite formation is basically inflammatory process, observed effects of genistein are responsible for its anti-cellulite action. Moreover, by inhibiting blood glucose concentration (hypoglycemic effect), genistein also contributes to lowering of fatty acids level and thus subsequently triglycerides biosynthesis [S. Y. Cheng, N. S. Shaw, K. S. Tsai, C. Y. Chen: The hypoglycemic effects of soy isoflavones on postmenopausal women, J. Womens Health (Larchmt) 13 (2004) 1080-1086; E. A. Pop, L. M. Fischer, A. D. Coan, M. Gitzinger, J. Nakamura, S. H.
  • the present invention relates to the formulation consisting of variable amounts of:
  • micronized zeolite (MZ) of general formula:
  • Me Na, K, Mg, Ca, Fe, Zn, Mn, Cr; whereas ratio of silicon to aluminum, y:x is between 6:1 to 1 :1; number of crystalline water m is from 0 to 20, which is characterized by particles size ⁇ 5 ⁇ m; in concentrations from 1-50%, most preferably from 3-30%;
  • Green tea extract containing at least 30% of epigallocatechin gallate (EGCG; 1), and 5% of caffeine (2); in concentrations from 0.1-90%, most preferably from 20-90%;
  • EGCG epigallocatechin gallate
  • excipients which yield in desired pharmaceutical or cosmetic form: tablets, capsules, ointments, creams, gels, lotions, shampoos, powders, liquid powders, syrups, suspensions, and therapeutic patches; in concentrations from 1-98.85%, most preferably from 10-75%.
  • the formulation from the present invention provides highly effective reduction of body weight and cellulite.
  • micronized zeolite clinoptilolite, or similar zeolites like zeolite A when administered orally with Green tea extract and genistein surprisingly does act as very effective composition for treatment of obesity and cellulite.
  • Silicon as essential microelement with a number of roles in human organism is biologically available in the form of ortho-silicic acid (H 4 SiO 4 ).
  • silicon acts as anti- inflammatoric in various conditions and diseases such as seborrheic dermatitis, neurodermitis, atopic dermatitis, skin irritations, disorders connected with decubitus, accelerates wound healing, and stimulates biosynthesis of skin building proteins collagen and elastin [C. D. Seaborn, F. H. Nielsen: Silicon deprivation decreases collagen formation in wounds and bone, and ornithine transaminase enzyme activity in liver, Biol. Trace Element Res. 89 (2002) 251; M. R. Calomme, D. A. V. Berghe: Supplementation of calves with stabilised orthosilicic acid effect on the Si, Ca, Mg and P concentration in serum and the collagen concentration in skin and cartilage, Biol. Trace Element Res. 56 (1997) 153].
  • silicon takes a part in the structure of arterial, veins, and capillary walls; increases elasticity and hardness of blood vessels, and decreased their permeability [K. Schwartz: A bound form of silicon in glycosaminoglycans and polyuronides, Proc. Nat. Acad. Set USA 70 (1973) 1608; E. M. Carlisle, D. L. Garvey: The effect of silicon on formation of extra-cellular matrix components by chondrocytes in culture, Fed. Proc. 41 (1982) 461; E. M. Carlisle, C. Suchil: Silicon and ascorbate interaction in cartilage formation in culture, Fed. Proc. 42 (1983) 398].
  • micronized zeolite clinoptilolite acts as effective pharmaceutically-acceptable source of highly bioavailable silicon.
  • MZ is capable of releasing soluble silicon even in neutral water, presumably in the form of ortho-silicic acid, as demonstrated by quantitative analyses of aqueous supernatants obtained after trituration of MZ in pure redistilled water [Novatech, PCT7HR2008/000030].
  • micronized zeolit clinoptilolite in all suitable pharmaceutical forms Na + , K + , Mg 2+ , Ca 2+ , Fe 2+ /Fe 3+ , Zn 2+ , Mn 2+ , Cr 3+ .
  • suitable pharmaceutical forms Na + , K + , Mg 2+ , Ca 2+ , Fe 2+ /Fe 3+ , Zn 2+ , Mn 2+ , Cr 3+
  • zeolite A can be used after micronization.
  • ortho-Silicic acid forms relatively stable complexes with ortho-diphenols like EGCG, and ⁇ -diketons or ⁇ -keto-enols (or analogous ⁇ -keto-phenols) such as genistein. In this manner it might enhance biological activity of these polyphenols by keeping their at sufficient concentrations in body fluids. This might occur due to decreased rate of their metabolism in liver through known polyphenols-elimination pathway by glucuronidation or sulfate-conjugation.
  • the formulation of the present invention is consisting of the mentioned components in the following concentrations:
  • micronized zeolite (MZ) of general formula:
  • Me Na, K, Mg, Ca, Fe, Zn, Mn, Cr; whereas ratio of silicon to aluminum, y:x is between 6:1 to 1 :1 ; number of crystalline water m is from 0 to 20, which is characterized by particles size ⁇ 5 ⁇ m; in concentrations from 1-50%, most preferably from 3-30%; (ii) Green tea extract containing at least 30% of epigallocatechin gallate (EGCG; 1), and 5% of caffeine (2); in concentrations from 0.1-90%, most preferably from 20-90%;
  • EGCG epigallocatechin gallate
  • excipients which yield in desired pharmaceutical or cosmetic form: tablets, capsules, ointments, creams, gels, lotions, shampoos, powders, liquid powders, syrups, suspensions, and therapeutic patches; in concentrations from 1-98.85%, most preferably from 10-75%.
  • Tablets, capsules, syrups, suspensions and therapeutic patches are preferred pharmaceutical forms for oral administration in treatment of obesity conditions, whereas forms such as ointments, creams, gels, lotions, shampoos, powders, liquid powders, and therapeutic patches are more suitable for topical treatment of cellulite.
  • Excipients are selected from the groups consisting of fillers, binders, disintegrants, lubricants, emollients, emulsifiers, tensides, humectants, solvents, thickeners, preservatives, antioxidants, stabilizers, and other functional additives which may help basic therapeutic action of above- defined main active substances.
  • fillers are selected from the group consisting of microcrystalline cellulose, lactose monohydrate, calcium hydrogenphosphate, sorbitol, starch, modified starches, etc.
  • the following substances can be used: talc, kaolin, bentonite, montmorillonite, precipitated calcium carbonate, basic magnesium carbonate, calcium silicate, aluminum hydroxide, silicon dioxide, or mixtures of these substances.
  • binders are selected from the group consisting of gelatin, lactose monohydrate, sorbitol, saccharose, xylitol, maltitol, mannitol, starch, modified starches, methylcellulose, 2-hydroxyethylcellulose, 2-hydroxypropylcellulose, sodium carboxymethylcellulose, polyethyleneglycols, polyglycerols, polyvinylpyrrolidone, polyvinylpyrrolidone co-polymers, carrageenans, or mixtures of these substances.
  • Disintegrants in solid dosage forms are selected from the group consisting of starch, modified starches, sodium starch glycolate, methylcellulose, sodium carboxymethylcellulose, 2- hydroxyethylcellulose, 2-hydroxypropylcellulose, polyvinylpyrrolidone, polyvinylpyrrolidone co-polymers, or mixtures of these substances.
  • Lubricants in solid dosage forms and powders are selected from the group consisting of: metal soaps such as magnesium stearate, calcium stearate, and zinc stearate; higher fatty acids like stearic acid; talc; silicon dioxide; or mixtures of these substances.
  • Emollients in semi-solid and liquid forms of the formulation for topical treatment of cellulite are selected from the group consisting of: paraffin wax; mineral oil; petroleum jelly; ozokerite; synthetic esters of higher fatty acids like isopropyl myristate, isopropyl palmitate, trimethylolpropane tristearate, glyceryl tricaprylate; natural waxes such as beeswax or spermaceti; liquid natural waxes such as jojoba oil; synthetic waxes such as lauryl laurate; plant oils such as soybean oil, sweet almond oil, sunflower seed oil, fish oil, olive oil, wheat germ oil, corn germ oil, avocado oil, palm oil, coconut oil; semi-solid or liquid silicones; higher fatty alcohols such as cetyl alcohol, stearyl alcohol, oleyl alcohol; or mixtures of these substances.
  • Emulsifiers in creams, ointments, and other forms of the formulation are selected from the group consisting of: metal salts of sulphates of higher fatty alcohols like sodium laurylsulphate, sodium lauryl ethyleneglycolsulphate, sodium lauryl diethyleneglycolsulphate; ethoxylates of higher fatty alcohols such as polyoxyethylene(2) laurylether, polyoxyethylene(l ⁇ ) laurylether, polyoxyethylene(23) laurylether, and others, where 2, 10 and 23 represent average number of ethyleneglycol units bounded on higher fatty alcohol; ethoxylates of higher fatty acids such as polyoxyethylene(2) laurate, polyoxyethylene(l ⁇ ) laurate, polyoxyethylene(23) laurate, and others, wherein 2, 10 and 23 represent average number of ethyleneglycol units bounded on higher fatty acid; esters of sorbitan such as polyoxyethylene sorbitan monolaurate; lanolin;
  • Tensides in liquid forms of the formulation like shampoos are selected from the group consisting of: metal salts of sulphates of higher fatty alcohols such as sodium laurylsulphate, sodium lauryl ethyleneglycolsulphate, sodium lauryl diethyleneglycolsulphate, potassium laurylsulphate, potassium lauryl ethyleneglycolsulphate, potassium lauryl diethyleneglycolsulphate, ammonium laurylsulphate, ammonium lauryl ethyleneglycolsulphate, ammonium lauryl diethyleneglycolsulphate, sodium or potassium cocoamphodipropionate; disodium or dipotassium cocoamphodiacetate; polyoxyethylene(l ⁇ ) laurylether, polyoxyethylene(23) laurylether, polyoxyethylene(l ⁇ ) stearylether, polyoxyethylene(23) stearylether, polyoxyethylene(l ⁇ ) oleylether, polyoxyethylene(23) oleylether, and other ethoxylates of higher
  • mono- or diethanolamides of higher fatty acids cocoamidopropyl betaine; glycosides of higher fatty alcohols like cocoglucoside; sodium or potassium di(2-ethylhexyl)sulfosuccinate; disodium or dipotassium 2-ethylhexylsulfosuccinate; cationic tensides such as cetyltrimethylammonium bromide, didecyldimethylammonium chloride, benzalkonium chloride, cetylbenzyldimethylammonium bromide, cetylpyridinium chloride; metal salts of higher fatty acids such as sodium or potassium salts of lauric, myristic, palmitic, stearic, oleic, or ricinoleic acid; or mixtures of these substances.
  • Humectants are selected from the group consisting of glycerol, 1 ,2-propyleneglycol, 1,3- propyleneglycol, hexyleneglycol, 1,3-butanediol, polyethyleneglycols, polyglycerols, sorbitol, xylitol, saccharose, urea, sodium hyaluronate, or mixtures of these substances.
  • Solvents in liquid forms of the formulation like lotions are selected from the group consisting of purified water, ethanol, 1-propanol, isopropanol, isosorbide dimethylether, diethyleneglycol monomethylether, diethyleneglycol dimethylether, diethyleneglycol monoethylether, diethyleneglycol diethylether, triethyleneglycol monomethylether, triethyleneglycol dimethylether, triethyleneglycol monoethylether, triethyleneglycol diethylether, ethyl lactate or other lactate esters with lower aliphatic alcohols, triethylhexanoin, or mixtures of these substances.
  • Thickeners in the formulation are selected from the group consisting of: polyacrylic acid, its co-polymers, or their sodium, potassium, or triethanolamine salts; methylcellulose; sodium carboxymethylcellulose; 2-hydroxyethylcellulose; 2-hydroxypropylcellulose; starch; modified starches; polyglycerols; polyethyleneglycols; gelatin; pectin; agar agar; carrageenans; gum arabic; alginic acid; sodium alginate; montmorillonite; bentonite; or mixtures of these substances.
  • Preservatives are selected from the group consisting of: methyl 4-hydroxybenzoate; ethyl 4- hydroxybenzoate; propyl 4-hydroxybenzoate; butyl 4-hydroxybenzoate; triclosan; chlorhexidine or its dihydrochloride, diacetate, or digluconate salts; sorbic acid; potassium sorbate; benzoic acid; sodium benzoate; 2-bromo-2-nitropropane-l,3-diol; 2- hydroxybiphenyl; 2-phenoxyethanol; 4-chloro-m-cresol; thymol; eugenol; methyl salicylate; or mixtures of these substances.
  • Antioxidants are selected from the group consisting of 2,6-di-terc-butyl-4-hydroxytoluene (BHT), terc-butylhydroxyanisole (BHA), tocopherol, tocopherol acetate, ascorbic acid, ascorbyl palmitate, or mixtures of these substances.
  • Stabilizers are selected from the group consisting of disodium ethylenediamine tetraacetate (Na 2 EDTAx2H 2 O), disodium N-(2-hydroxyethyl)ethylenediamine triacetate
  • Anti-inflammatory and/or antiphlogistic agent is selected from the group consisting of: paracetamol; metamizol sodium; acetylsalicylic acid and its salts with pharmaceutically acceptable bases; salicylic acid and its salts with pharmaceutically acceptable bases; salsalate; methyl salicylate; ethyl salicylate; benzyl salicylate; 2-hydroxyethyl salicylate; salicylamide; phenylbutazone sodium; propyphenazone; oxyphenbutazone; mofebutazone; bumadizon calcium; phenazone; ethenzamide; ketoprofen, ibuprofen, naproxen, flurbiprofen, pirprofen, mefenamic acid, fluphenamic acid, thiaprofenic acid or their salts with pharmaceutically acceptable bases; diclofenac sodium; indomethacin; piroxicam; meloxicam; codeine; caffeine; extract of St John's wort (Hy
  • Antioxidant is selected from the group consisting of: extract of Rooibos (Aspalathus linearis); extract of Nettle (Urtica dioica); extract of Bilberry (Vaccinium myrtillus); extract of Orange (Citrus aurantium); silymarin; extract of Milk Thistle (Silybum marianum); ascorbic acid, its salts, and esters such as ascorbyl palmitate; tocoferol; tocoferol acetate; niacinamide; rutin; quercetin; extracts of plants with significant content of rutin and/or quercetin; cyanidin; hesperidin; diosmin; lycopene; extracts of plants with significant contents of lycopene; resveratrol; tetrahydrocurcumin; rosmarinic acid; extract of Rosemary (Rosmarinus officinalis); hypericin; extract of St John's wort (Hypericum perforatum); ella
  • Astringent is selected from the group consisting of: zinc oxide; zinc stearate; zinc tannate; zinc acetate; zinc sulphate; zinc chloride; iron(III) chloride; aluminum sulphate; potassium aluminum sulphate; aqueous basic aluminum acetate; aluminum acetotartarate; bismuth subnitrate; bismuth subcarbonate; bismuth phosphate; bismuth tannate; calamine; copper(II) sulphate; silver nitrate; silver-proteine; aescin; extract of Horse-Chestnut (Aesculus hippocastanum); Balsam of Peru; silica gel; kaolin; talc; titanium dioxide; tannic acid; albumin tannate; methylene ditannate; extracts with significant content of tannins such as extracts of Oak bark (Cortex Quercus ruber, Quercus sessiliflora), Bearberry leaves (Arctostaphylos uvae
  • Skin tonifying agents are selected from the group consisting of: vitamins and pro-vitamins like retinol palmitate, ⁇ -carotene, niacinamide, d-panthenol, calcium pantothenate, folic acid, riboflavin, pyridoxine, thiamine, biotin, cyanocobalamin, ascorbic acid its salts and esters such as ascorbyl palmitate, cholecalciferol, tocopherol, tocopherol acetate, phylloquinone, menaquinone, menadione; animal and plant oils with high contents of omega-3 higher fatty acids such as fish or linseed oil; choline chloride; protein hydrolysates; algae extracts; extract of Witch-hazel (Hamamelis virginiana); extract of Centaurium (Erythraea centaurum); extract of Mullein (Verbascum phlomoides); extract of European Holly (Ilex aquifoli
  • the formulation of the present invention can be in the form of tablets, capsules, ointments, creams, gels, lotions, shampoos, powders, liquid powders, syrups, suspensions, and therapeutic patches.
  • the formulations are produced by common procedures known to those skilled in the art of cosmetic and/or pharmaceutical technology [S. C. Gad (Ed.): Pharmaceutical Manufacturing Handbook: Production and Processes, Wiley (2008)]. Several possible variations are possible but which essentially remain under the scope of this invention. EXAMPLES
  • micronized zeolite (MZ) in all possible forms Na, K, Mg, Ca, Fe, Zn, Mn, Cr
  • Zeolite A and natural clinoptilolite were purchased and micronized in our laboratory.
  • room temperature means: 20-25 0 C.
  • Composition per cps 50 mgs of genistein; 390 mgs of Green tea extract (corresponds to 175 mgs of EGCG and 40 mgs of caffeine); and 50 mgs of micronized clinoptilolite.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/HR2009/000005 2009-02-24 2009-02-24 Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite WO2010097643A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/HR2009/000005 WO2010097643A1 (en) 2009-02-24 2009-02-24 Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/HR2009/000005 WO2010097643A1 (en) 2009-02-24 2009-02-24 Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite

Publications (1)

Publication Number Publication Date
WO2010097643A1 true WO2010097643A1 (en) 2010-09-02

Family

ID=41212176

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HR2009/000005 WO2010097643A1 (en) 2009-02-24 2009-02-24 Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite

Country Status (1)

Country Link
WO (1) WO2010097643A1 (en11)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012156913A1 (en) * 2011-05-18 2012-11-22 Slavko Ivkovic An antioxidant composition
WO2013055197A1 (es) * 2011-10-12 2013-04-18 Universidad Autonoma Del Estado De Hidalgo Polvo base a partir de frambuesa roja rubus idaeus y zeolita activada y micronizada para atenuar la adiccion a la nicotina, proceso para su preparación y su uso
WO2013074046A1 (en) * 2011-08-08 2013-05-23 Mahmut Bilgic Pharmaceutical formulations comprising isoflavone
CN103642574A (zh) * 2013-12-20 2014-03-19 江苏鹏飞海太机械有限公司 一种织机润滑油
WO2015017336A1 (en) * 2013-07-29 2015-02-05 OmniGen Research, L.L.C. Combination and method for administration to an animal
US9375408B2 (en) * 2014-09-02 2016-06-28 Bhupinder Singh Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
WO2016183633A1 (en) * 2015-05-19 2016-11-24 Sndr Pty Ltd Skin cleansing composition
CN106268810A (zh) * 2016-07-29 2017-01-04 华南理工大学 一种表面复合修饰颗粒聚集体载体材料及制备方法与应用
CN108997154A (zh) * 2018-08-27 2018-12-14 山东祥维斯生物科技股份有限公司 具有低氯化钠含量和低吸湿性的甜菜碱制剂制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040699A1 (en) * 1996-04-25 1997-11-06 Unilever Plc Tea processing with zeolites
US20060153926A1 (en) * 2005-01-10 2006-07-13 Bascom Charles C Compositions, products and methods for controlling weight in a mammal
CN101218962A (zh) * 2007-12-26 2008-07-16 中国科学院东北地理与农业生态研究所 一种改善牛奶品质的饲料添加剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040699A1 (en) * 1996-04-25 1997-11-06 Unilever Plc Tea processing with zeolites
US20060153926A1 (en) * 2005-01-10 2006-07-13 Bascom Charles C Compositions, products and methods for controlling weight in a mammal
CN101218962A (zh) * 2007-12-26 2008-07-16 中国科学院东北地理与农业生态研究所 一种改善牛奶品质的饲料添加剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200856, Derwent World Patents Index; AN 2008-J52094, XP002553961, LIZ; LIU C; SUN H: "Feedstuff additive for use in improving milk" *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012156913A1 (en) * 2011-05-18 2012-11-22 Slavko Ivkovic An antioxidant composition
WO2013074046A1 (en) * 2011-08-08 2013-05-23 Mahmut Bilgic Pharmaceutical formulations comprising isoflavone
US20150216921A1 (en) * 2011-10-12 2015-08-06 University of Hidalgo Base powder from the red raspberry rubus idaeus and activated micronized zeolite for attenuating nicotine addiction, method for the preparation thereof and use thereof
WO2013055197A1 (es) * 2011-10-12 2013-04-18 Universidad Autonoma Del Estado De Hidalgo Polvo base a partir de frambuesa roja rubus idaeus y zeolita activada y micronizada para atenuar la adiccion a la nicotina, proceso para su preparación y su uso
EP2767281A4 (en) * 2011-10-12 2015-05-20 Univ Autonoma Del Estado De Hidalgo POWDER BASE FROM RUBUS IDAEUS RED RASPBERRY AND ACTIVATED AND MICRONIZED ZEOLITE TO ATTENUATE NICOTINE ADDICTION, PROCESS FOR THE PREPARATION AND USE
WO2015017336A1 (en) * 2013-07-29 2015-02-05 OmniGen Research, L.L.C. Combination and method for administration to an animal
CN103642574A (zh) * 2013-12-20 2014-03-19 江苏鹏飞海太机械有限公司 一种织机润滑油
US9375408B2 (en) * 2014-09-02 2016-06-28 Bhupinder Singh Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
US10781158B2 (en) 2014-09-02 2020-09-22 Bhupinder Singh Methods of protecting an organ using tetrahydrocurcumin and phosphatidylcholine
WO2016183633A1 (en) * 2015-05-19 2016-11-24 Sndr Pty Ltd Skin cleansing composition
CN106268810A (zh) * 2016-07-29 2017-01-04 华南理工大学 一种表面复合修饰颗粒聚集体载体材料及制备方法与应用
CN108997154A (zh) * 2018-08-27 2018-12-14 山东祥维斯生物科技股份有限公司 具有低氯化钠含量和低吸湿性的甜菜碱制剂制备方法
CN108997154B (zh) * 2018-08-27 2021-05-11 山东祥维斯生物科技股份有限公司 具有低氯化钠含量和低吸湿性的甜菜碱制剂制备方法

Similar Documents

Publication Publication Date Title
WO2010097643A1 (en) Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite
WO2010018418A1 (en) Formulation based on micronized clinoptilolite as therapeutic agent providing highly bioavailable silicon
IL260028B1 (en) Baby care products
CN115607510B (zh) 一种高浓度齐墩果酸纳米乳组合物及制备方法
US20190008907A1 (en) Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases
MX2008012654A (es) Composiciones novedosas para trastornos del cabello, y procedimiento de preparacion de las mismas.
CN102342993B (zh) 一种皮肤抗敏修复外用制剂
CA3148643A1 (en) Topical formulations comprising cannabidiol, method of preparing the composition and use thereof
WO2019234743A1 (en) Anti-inflammatory synergistic compositions comprising cannabinoids and licorice
CN101842089A (zh) 用于刺激前胶原蛋白或胶原蛋白和透明质酸合成的方法
US20040214750A1 (en) Medicaments for healing skin conditions in humans
WO2014095049A1 (en) Compositions for the treatment of dermatological conditions, disorders or diseases
EP2885004A1 (en) Companion cosmetic compositions
US20060083708A1 (en) Composition using mineral salts for cosmetic or therapeutic treatment
ES2340510T3 (es) Uso de alquil-furanos para la preparacion de un medicamento destinado al tratamiento de la obesidad y para el tratamiento cosmetico del exceeso de peso.
US8383166B2 (en) Stable hydrophobic topical herbal formulationn
JP2015513558A (ja) 美容組成物
Semkina Ointments, gels, liniments, and creams containing phytopreparations (a review)
US8507007B2 (en) Dermatological composition that can be used in particular for the care and prevention of eschars
Mascolo et al. Healing powers of aloes
EP0717613B1 (en) Stable composition containing wheat sprout juice and process for producing it
Haji et al. Ghee based nanostructured lipid carriers (NLCs) with improved wound-healing effects: Ghee based nanostructured lipid carriers (NLCs)
JP6853406B1 (ja) 抗毛嚢炎用外用組成物
ITUB20159582A1 (it) Composizione, per uso topico, utile per la prevenzione di disturbi di tipo infiammatorio e/o infettivo delle mucose.
ES2581180B1 (es) Uso de aloe oral para la mejora capilar

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09785745

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 01/12/2011)

122 Ep: pct application non-entry in european phase

Ref document number: 09785745

Country of ref document: EP

Kind code of ref document: A1